50 Northern Ave
Boston, MA, 02210 United States
S&P 500 (June 30, 2014)
Vertex Pharmaceuticals aims to cure patients with previously incurable diseases. The biotechnology company uses an integrated, multidisciplinary approach -- employing biophysics, computer-based modeling, and functional genomics -- to speed up the discovery and development of new drugs. Its first commercial product, Incivek (telaprevir) for hepatitis C virus (HCV), was launched in 2011, and a second drug for cystic fibrosis, Kalydeco, was launched in 2012. The company has other drugs in development, including additional treatments for HCV and cystic fibrosis, as well as epilepsy and rheumatoid arthritis.